Oppenheimer upgrades Relay Therapeutics (RLAY) to Outperform, citing the strength of its mutant-selective inhibitor pipeline and upcoming catalysts in the breast cancer treatment arena.
As Microsoft shares trade nearly 12% below recent highs, some analysts see a buying opportunity. We explore how selling put options could offer investors a strategic entry point while generating income.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
The Hennepin County Medical Examiner has officially classified the January shooting death of ICU nurse Alex Pretti as a homicide, a finding that intensifies legal and public pressure on the federal agents involved amid ongoing protests and disputed official narratives.
As artificial intelligence reshapes finance, we examine whether XRP's underlying technology is built to capitalize on the trend of 'agentic AI' handling transactions, or if its potential benefits remain speculative.
Terex Corporation shares gained over 4% following the finalization of its merger with REV Group, creating a diversified specialty equipment giant. The deal is projected to yield $75 million in annual synergies by 2028.
Shares of Werner Enterprises (WERN) surged 6% following the announcement of its acquisition of FirstFleet, a move that significantly bolsters its dedicated transportation division and market position.
Shares of Super Micro Computer (SMCI) advanced Thursday after Rosenblatt Securities reiterated its Buy rating, with investors eyeing potential benefits from NVIDIA's next-generation AI chips and easing supply constraints.
In a strategic move to unify its product and technology vision, Netflix has elevated CTO Elizabeth Stone to the newly created role of Chief Product and Technology Officer. The promotion places her at the helm of the streaming giant's core product, engineering, and data divisions.
WK Kellogg Co. names former Ferrero executive Jean-Baptiste Santoul as Chief Operating Officer, signaling a strategic shift following its $3.1 billion acquisition by the global confectionery giant.
While the S&P 500 remains a core holding for many, actively managed and thematic ETFs offer a path to potentially superior returns. We analyze three Fidelity funds with distinct strategies—from U.S. tech dominance to international dividend income—that have historically beaten the market.
The medical device developer Beta Bionics has received a warning letter from the U.S. Food and Drug Administration, a regulatory action stemming from a facility inspection last summer. The company maintains the letter will not disrupt its operations, manufacturing, or the planned launch of its new insulin patch pump.
Franklin Templeton has launched the Templeton Emerging Markets Debt ETF (TEMD), aiming to give investors targeted exposure to both hard and local currency debt from developing economies, capitalizing on the asset class's recent strong performance.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
A discounted cash flow valuation of GrainCorp Limited suggests its current share price may not fully reflect its future cash generation potential, indicating a possible opportunity for investors.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
PLS Group (ASX:PLS) receives significant forecast upgrades from analysts, with revenue projections for 2026 raised to AU$1.6b and the company expected to return to profitability this year.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
A historic winter storm has plunged American Airlines into its worst weather-related crisis, stranding crews and passengers while wiping up to $200 million from its revenue, exposing deep-seated recovery challenges.
